BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 19205695)

  • 1. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions.
    Tian R; Su M; Tian Y; Li F; Li L; Kuang A; Zeng J
    Skeletal Radiol; 2009 May; 38(5):451-8. PubMed ID: 19205695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-time point
    Parghane RV; Basu S
    Semin Nucl Med; 2017 Jul; 47(4):373-391. PubMed ID: 28583277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
    Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
    Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
    Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S
    Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-time-point 18F-FDG PET for the evaluation of gallbladder carcinoma.
    Nishiyama Y; Yamamoto Y; Fukunaga K; Kimura N; Miki A; Sasakawa Y; Wakabayashi H; Satoh K; Ohkawa M
    J Nucl Med; 2006 Apr; 47(4):633-8. PubMed ID: 16595497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Differentiation of malignant and benign superficial lymph nodes by dual time point 18F-FDG PET].
    Su MG; Fan QP; Tian Y; Li FL; Yang XC; Li L; Fan CZ; Tian R
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 May; 40(3):517-20. PubMed ID: 19627018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited predictive value of dual-time-point F-18 FDG PET/CT for evaluation of pathologic N1 status in NSCLC patients.
    Kim SJ; Kim YK; Kim IJ; Kim YD; Lee MK
    Clin Nucl Med; 2011 Jun; 36(6):434-9. PubMed ID: 21552019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of solitary thyroid nodule on 18F-FDG PET/CT and high-resolution ultrasonography.
    D'Souza MM; Marwaha RK; Sharma R; Jaimini A; Thomas S; Singh D; Jain M; Bhalla PJ; Tripathi M; Tiwari A; Mishra A; Mondal A; Tripathi RP
    Ann Nucl Med; 2010 Jun; 24(5):345-55. PubMed ID: 20373060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-time-point [18F]-FDG PET/CT in the diagnostic evaluation of suspicious breast lesions.
    Caprio MG; Cangiano A; Imbriaco M; Soscia F; Di Martino G; Farina A; Avitabile G; Pace L; Forestieri P; Salvatore M
    Radiol Med; 2010 Mar; 115(2):215-24. PubMed ID: 20017002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual time point 2-[18F]fluoro-2'-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis.
    Sahlmann CO; Siefker U; Lehmann K; Meller J
    Nucl Med Commun; 2004 Aug; 25(8):819-23. PubMed ID: 15266177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of delayed 18F-FDG PET in differential diagnosis for malignant soft-tissue tumors.
    Hamada K; Tomita Y; Ueda T; Enomoto K; Kakunaga S; Myoui A; Higuchi I; Yoshikawa H; Hatazawa J
    Ann Nucl Med; 2006 Dec; 20(10):671-5. PubMed ID: 17385305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical usefulness of dual-time FDG PET-CT in assessment of esophageal squamous cell carcinoma.
    Shum WY; Hsieh TC; Yeh JJ; Chen JH; Su CC; Liang JA; Kao CH
    Eur J Radiol; 2012 May; 81(5):1024-8. PubMed ID: 21458941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic usefulness of FDG PET for pancreatic mass lesions.
    Koyama K; Okamura T; Kawabe J; Nakata B; Chung KH; Ochi H; Yamada R
    Ann Nucl Med; 2001 Jun; 15(3):217-24. PubMed ID: 11545191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited prognostic value of dual time point F-18 FDG PET/CT in patients with early stage (stage I & II) non-small cell lung cancer (NSCLC).
    Kim SJ; Kim YK; Kim IJ; Kim YD; Lee MK
    Radiother Oncol; 2011 Jan; 98(1):105-8. PubMed ID: 21159395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-time-point FDG PET/CT for the evaluation of pediatric tumors.
    Costantini DL; Vali R; Chan J; McQuattie S; Charron M
    AJR Am J Roentgenol; 2013 Feb; 200(2):408-13. PubMed ID: 23345365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standardized uptake value-based evaluations of solitary pulmonary nodules using F-18 fluorodeoxyglucose-PET/computed tomography.
    Degirmenci B; Wilson D; Laymon CM; Becker C; Mason NS; Bencherif B; Agarwal A; Luketich J; Landreneau R; Avril N
    Nucl Med Commun; 2008 Jul; 29(7):614-22. PubMed ID: 18528183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of dual-phase 18F-FDG PET in characterizing thyroid incidentalomas.
    Hsiao YC; Wu PS; Chiu NT; Yao WJ; Lee BF; Peng SL
    Clin Radiol; 2011 Dec; 66(12):1197-202. PubMed ID: 21907336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of solitary pulmonary nodules with 18F-FDG PET/CT relative activity distribution analysis.
    Zhao L; Tong L; Lin J; Tang K; Zheng S; Li W; Cheng D; Yin W; Zheng X
    Eur Radiol; 2015 Jul; 25(7):1837-44. PubMed ID: 25636419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.